RxDoctor Payments Data

Arvind Ankireddypalli, MD

Geriatric Medicine · Memphis, TNNPI 1003162637

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Novo Nordisk at 44.4% of the total. Reporting peaked in 2022 at $284 and has fallen 72.3% since, to $79 in 2025.

$537in general payments, 2019–2025

Across 6 payments — averaging $89.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$238
  • Abiomed$125
  • Veloxis Pharmaceuticals, Inc.$96
  • Bayer$79

What the payments were for

  • Food & beverage$537100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk3$238
Abiomed1$125
Veloxis Pharmaceuticals, Inc.1$96
Bayer1$79

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$537 in reported general payments places this provider in the 70th percentile of 46 geriatric medicine providers in Tennessee.

See all geriatric medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$582,384
Medicare patients
9,926
Services billed
46,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$138,580
OzempicSemaglutide90$118,736
TradjentaLinagliptin109$117,118
JardianceEmpagliflozin103$115,581
MounjaroTirzepatide75$86,492
JanuviaSitagliptin Phosphate83$86,283
TrulicityDulaglutide53$62,508
FarxigaDapagliflozin Propanediol45$39,162
LinzessLinaclotide40$35,043
XareltoRivaroxaban25$26,925
Bydureon BciseExenatide Microspheres17$20,820
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$15,511
Breo ElliptaFluticasone/Vilanterol37$13,711
BrilintaTicagrelor24$12,718
Tresiba Flextouch U-100Insulin Degludec13$10,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$238$118,73690 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 46 geriatric medicine providers in Tennessee.

Other geriatric medicine in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →